Disease
|
Drug/Important Bio-Agent (IBA)
3 | RadiopharmaceuticalsIBA
01/2015
-
04/2013 |
2 | phosphonic acidIBA
06/2019
-
01/2015 |
2 | Lutetium-177IBA
01/2018
-
05/2013 |
2 | Rituximab (Mabthera)FDA Link
05/2017
-
04/2013 |
1 | ethylenediamine (ethylenediamine dihydroiodide)FDA Link
06/2019 |
1 | Metal-Organic FrameworksIBA
01/2018 |
1 | 1,4,7,10- tetraazacyclododecane- 1,4,7,10- tetrakis(methylenephosphonic acid) (DOTMP)IBA
01/2018 |
1 | Therapeutic UsesIBA
05/2017 |
1 | tetramethylenedisulfotetramine (DSTA)IBA
01/2015 |
1 | holmium- 1,4,7,10- tetraazacyclododecane- N,N',N'',N'''- tetrakis(methylenephosphonic acid)IBA
12/2014 |
1 | Small Interfering RNA (siRNA)IBA
05/2013 |
1 | Monoclonal AntibodiesIBA
04/2013 |
1 | Pentetic Acid (DTPA)FDA LinkGeneric
04/2013 |
1 | Pamidronate (Aredia)FDA LinkGeneric
01/2013 |
1 | lutetium ethylenediaminetetramethylene phosphonic acidIBA
01/2012 |
|
Therapy/Procedure
|